Alloreactive donor T cell

“Alloreactive donor T cells” are not a single molecular receptor or protein but rather **donor-derived T lymphocytes whose T cell receptors recognize alloantigens (primarily mismatched human leukocyte antigen/major histocompatibility complex molecules) in the transplant recipient**.[1][7][8] These cells are central effectors of alloimmune responses in hematopoietic stem cell and solid organ transplantation, mediating graft-versus-host disease, host-versus-graft rejection, and long-lived memory responses to alloantigen.[1][2][3][7] Alloreactive donor T cells exhibit high precursor frequencies compared with conventional antigen-specific responses, show characteristic metabolic reprogramming (enhanced glycolysis and oxidative phosphorylation) upon activation, and can differentiate into effector and memory subsets that infiltrate target tissues and sustain inflammation and tissue damage.[1][2][4][5][7] They are therefore an important **cellular therapeutic target population** for immunosuppressive and cell-engineering strategies, but the query term itself does not refer to a discrete druggable receptor or enzyme.

Other names

Alloreactive T cellAlloimmune T cellDonor alloreactive T cellAllogeneic reactive T cell

Depletion of alloreactive donor T cells via polyclonal anti-T-cell antibodies, reducing graft-versus-host and graft-versus-host/host-versus-graft responses[9][7] Inhibition of T cell receptor–driven activation and IL-2–dependent proliferation of alloreactive T cells via calcineurin inhibition[7] Inhibition of mTOR-dependent metabolic and proliferative reprogramming required for alloreactive T cell effector differentiation[4][7] Blockade of costimulatory pathways required for priming and expansion of alloreactive T cells[5][7] Targeted depletion or functional inhibition of activated CD25⁺ alloreactive donor T cells to reduce graft-versus-host disease while preserving other immune functions[9]